Immix Biopharma, Inc. (NASDAQ:IMMX) Sees Significant Growth in Short Interest

Immix Biopharma, Inc. (NASDAQ:IMMX) was the recipient of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 470,700 shares, an increase of 17.5% from the November 15th total of 400,700 shares. Based on an average trading volume of 159,400 shares, the days-to-cover ratio is presently 3.0 days. Approximately 2.9% of the company’s shares are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Immix Biopharma stock. Invst LLC purchased a new position in shares of Immix Biopharma, Inc. (NASDAQ:IMMX) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 27,000 shares of the company’s stock, valued at approximately $57,000. Invst LLC owned about 0.10% of Immix Biopharma at the end of the most recent reporting period. Institutional investors own 11.26% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Immix Biopharma in a research note on Thursday, October 3rd.

Immix Biopharma Stock Performance

Shares of IMMX traded up $0.05 during mid-day trading on Monday, hitting $2.09. 75,410 shares of the company’s stock were exchanged, compared to its average volume of 184,148. The stock’s 50-day moving average is $1.78 and its 200-day moving average is $1.93. Immix Biopharma has a fifty-two week low of $1.26 and a fifty-two week high of $7.75. The company has a market cap of $57.49 million, a price-to-earnings ratio of -2.47 and a beta of 0.28.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.08). As a group, equities research analysts anticipate that Immix Biopharma will post -0.64 EPS for the current year.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.